Pravastatin in Polycystic Kidney Disease

Effect of Pravastatin on Kidney Function in Polycystic Kidney Disease

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12608000447358

Enrollment

100

Registered

2008-09-08

Start date

1998-01-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Polycystic kidney disease is a common cause of kidney failure Statins may slow kidney disease progression. This study aimed to assess whether pravastatin 20mg could slow the progression of kidney disease

Interventions

Pravastatin 20mg orally daily for 2 years

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

Polycystic kidney disease

Exclusion criteria

Females of Child bearing potential

Outcome results